STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca, according to Pharmaphorum, launched a three-year cost-cutting program aimed at removing $1.5 billion a year, with the savings reinvested in R&D.
- AstraZeneca estimates the program carries a one-time charge of around $2 billion and is expected to be completed by the end of 2029, while job implications remain unstated.
- Farxiga, the diabetes blockbuster, has lost patent protection, while three cancer drugs are among AstraZeneca’s major brands due to lose exclusivity between now and the mid-2030s.
- Sun Pharma, according to Reuters, was ordered on Aug. 20 by CDSCO and the Office of Drugs Controller Assam to stop manufacturing, selling and distributing ophthalmic products made at its Assam facility after a joint federal-state inspection found quality-management lapses.
- Sun Pharma had voluntarily recalled about 11 eye-care brands in July before the Aug. 20 order, which followed inspectors’ identification of lapses in the quality system meant to ensure product quality and safety.
- Sun Pharma previously said the Assam facility was expected to become one of its largest manufacturing hubs for sterile products, within a business it identified as a key global growth driver.
Why it matters: Sun Pharma’s Assam-made eye-care operation was halted after regulators found quality-management lapses and the company recalled about 11 brands. The site had been slated to become one of its largest manufacturing hubs for sterile products, so the Aug. 20 order interrupts its planned role in a business Sun had identified as a key global growth driver.
Ask SkimNews
